Rain Therapeutics Inc. (RAIN) News
Filter RAIN News Items
RAIN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RAIN News Highlights
- RAIN's 30 day story count now stands at 2.
- Over the past 1 day, the trend for RAIN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AMP, LI and UL are the most mentioned tickers in articles about RAIN.
Latest RAIN News From Around the Web
Below are the latest news stories about RAIN ONCOLOGY INC that investors may wish to consider to help them evaluate RAIN as an investment opportunity.
Rain Oncology to be acquired by Pathos AI for $1.16 in cash per shareMore on Rain Oncology |
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value RightsNEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger A |
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business UpdateNEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations. “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We anticipate being able to provide a public update on our efforts before |
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs. Rain’s Board of Directors and management team |
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain |
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: |
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma (DD LPS) are ongoing with data and findings to be presented at a medical conference in 4Q23 – – Company continuing to evaluate opportunities for expansion of its pipeline across precision oncology strategies – – Overall workforce reduction |
4 big analyst cuts: Apple loses buy rating on slack iPhone demandHere is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Apple, Revolve, Rain Therapeutics, and Intercept Pharmaceuticals. Loop Capital downgraded Apple (NASDAQ:AAPL) to Hold from Buy with a price target of $180.00. The firm sees a material downside risk to revenue (both iPhone and overall) estimates for Q3, relative to both the company’s guidance and Street forecasts. |
Why Shares of Rain Oncology Are Plummeting TodayShares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in the arms and legs. Rain said that milademetan, an inhibitor of the MDM2-p53 complex that reactivates p53, a known tumor inhibitor, taken orally, did not meet its primary endpoint of efficacy in a phase 3 trial to treat patients with dedifferentiated (DD) liposarcoma (LPS). Based on the disappointing results, Rain said it does not plan to pursue further development of the therapy to treat DD LPS. |